Shire and New River Pharmaceuticals have received FDA approval to market Vyvanse (lisdexamfetamine dimesylate), for the treatment of attention deficit hyperactivity disorder (ADHD). Vyvanse is a prodrug that is therapeutically inactive until metabolized in the body. In clinical trials, patients 6–12 years old treated with Vyvanse demonstrated statistically significant improvements in ADHD symptoms compared to patients treated with placebo for a full treatment day, up through and including 6pm. Vyvanse will be available in 30mg, 50mg, and 70mg dosage strengths.
For more information visit www.ShireADHDTreatments.com.